Glucagon (22-29)

Glucagon (22-29) is partial agonist of Glucagon (19–29) . Glucagon specifically inhibits the Ca2+ pump in liver plasma membranes independently of adenylate cyclase activation[1][2].

Product Specifications

CAS Number

[32204-93-6]

UNSPSC

12352209

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/glucagon-22-29.html

Purity

99.69

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC3=CC=CC=C3)N

Molecular Formula

C49H71N11O12S

Molecular Weight

1038.22

References & Citations

[1]Mallat A, et al. A glucagon fragment is responsible for the inhibition of the liver Ca2+ pump by glucagon. Nature. 1987 Feb 12-18;325 (6105) :620-2.|[2]Pavoine C, et al. Miniglucagon [glucagon- (19-29) ] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260 (5 Pt 1) :C993-9.